GHK-Cu Dosage Guide 2026: The Research vs Reported Use

The calculator

Milligrams in, syringe marks out: it takes a vial size, a water amount, a syringe type and a dose in milligrams, and returns the concentration, the volume, and what that volume reads as on the barrel.

GHK-Cu peptide injection dosage chart: what each study actually gave

What this chart is: every GHK-Cu amount we could trace to a named source, with the form it was given in, the species it was given to, and the route. Read those three columns before the number, because on this compound they change what the number means entirely.

One compound, four spellings: GHK-Cu, GHK Cu, ghk cu and ghkcu are the same copper peptide, the tripeptide glycyl-l-histidyl-l-lysine bound to a copper ion. Search boxes and vendor listings split across all four spellings. The chemistry does not.

The empty row is the finding: there is no row on this chart where a person was injected with GHK-Cu at a stated dose in a published trial. Every human study row is topical. Every injected row is a mouse. The review row is a review rather than a study, and its own conclusion on GHK-Cu is that the clinical data is not there. The last row is the only injected human figure anywhere on this page, and it comes from forum convention and vendor calculators.

Which is why a topical figure must not be read as an injectable one: 0.4% is a cream strength, not a dose. It is not a milligram amount, it never went into a syringe, and it does not convert into one. A page that lists a cream percentage beside injectable milligram numbers has quietly merged two different products.

A unit trap worth naming: the mouse figures are written in micrograms per gram of body weight. One microgram per gram is the same ratio as one milligram per kilogram, so the top mouse amount of 20mcg per g per day and 20mg per kg per day are the same thing written two ways. That identity is arithmetic, and it is worth having before comparing any animal figure to anything.

What this page will not do with those rows: convert a mouse milligram-per-kilogram figure into a human number. Nothing in the sources at the bottom performs that conversion, so neither do we. The conversion further down is milligrams into syringe units, which is arithmetic and holds regardless.

GHK-Cu cycle length, and how often it gets injected

The frequencies in the published record, by route: the mouse study injected on alternate days, from the first day after cigarette-smoke exposure, in animals exposed for 12 weeks. That is the whole list. Neither of the two human trial abstracts states an application frequency, so this page does not supply one for them.

For injection in a person, there is no frequency in the record, because there is no trial to take one from. The 2026 sports-medicine review says it in as many words: indications, dosing, frequency and duration of treatment remain unknown.

Cycle length has the same shape of answer: one duration exists in the record, an alternate-day injection schedule running alongside a 12-week smoke exposure in the mouse model. That is a real duration from a real protocol. It is not a ghkcu cycle for a person, and there is no published one to put in its place.

What a ghk cu cycle length answer would have to contain: a trial that injected people, ran for a stated number of weeks, and stopped. None of the human records on this page does that. Bishop 1992 and Miller 2006 are topical and state no application frequency at all. A cycle needs a start, a duration and a stop, and the published record supplies all three only for mice.

Time of day: nothing in the cited record specifies a time of day for any route.

The community answer, labeled as such: the posts summarized below describe once daily or several times a week, in blocks of about 30 days. That is convention, and it is recorded here as convention rather than restated as a finding.

Does the research dose match the internet dose?

Why the left-hand column is nearly empty: with GHK-Cu there is no injectable trial to set against the forum figures at all, so this is not a trial-versus-forum comparison in the ordinary sense. It is a record of what exists, beside a record of what people do anyway.

Every human trial in the reference list below put this peptide on skin. Every injected dose in it went into a mouse.

The question the evidence cannot reach: a null cream trial and a 13-completer satisfaction result carry no information about an injection, in either direction. The comparison above is not close, and it is not even a comparison; it is two records that never meet.

GHK-Cu reconstitution: the 50mg and 100mg vials, worked out

The two presentations that actually exist: 50mg and 100mg are the vial sizes that turn up in the listings and the protocol pages, and they are what the ghk cu reconstitution queries are asking about. The question underneath all of them is how much bacteriostatic water goes in.

There is no correct answer to that, and that is not a dodge. The water volume is a choice, not a property of the vial, and the choice is what sets the concentration. What can be settled is the arithmetic each choice produces, which is what the table does.

What the table is really showing is resolution: a 100mg vial in 2mL puts 0.5mg into every single unit mark. On that mix a 1mg figure is two units wide, so one unit of misreading moves the amount by half a milligram. The same vial in 5mL puts 0.2mg in a unit, the same figure spans five units, and a one-unit misread moves it by 0.2mg instead.

The vial did not change. The arithmetic did. That is the whole reason two ghkcu charts built on the same 50mg vial can print different unit counts and both be right: they are not disagreeing about the peptide, they are using different water. That failure gets taken apart in our note on charts that print different unit counts for one vial, and the general form of the arithmetic sits in concentration versus dose and the reconstitution calculator.

One input the table cannot check: every row above starts from the milligram figure printed on the vial, and nothing in the division verifies it. That figure is an assertion by whoever filled the vial, and the rest of the table is only downstream of it.

How does the units math work?

Why the copper peptide is the awkward one: the vials are labeled in tens of milligrams, 50mg and 100mg, so one barrel mark lands in tenths of a milligram instead of in micrograms and the familiar unit counts all shrink. The arithmetic below is general, and no figure in it belongs to anyone.

The 50mg vial, the one in the listings: with 2mL of bacteriostatic water a 50mg vial comes out at 25mg per mL, or 25,000mcg per mL.

A quarter of a milligram per unit: the U-100 barrel puts 100 units in a milliliter, so at this concentration one unit holds 250mcg, or 0.25mg. From there: 1mg is 4 units, and 2mg is 8 units.

One more milliliter of water: the same 50mg vial taken to 3mL instead of 2mL falls to about 16.7mg per mL.

The same milligram spread across more marks: a mark now holds about 0.167mg rather than 0.25mg, so that identical 1mg is 6 units, not 4, and 2mg reads as 12 units.

The 100mg vial goes the other way: at 2mL it sits at 50mg per mL, half a milligram to a mark, and 2mg reads as 4 units.

Eight units, two different milligram amounts: a unit count only travels with the water volume that produced it. Detached from that, 8 units names 2mg on one of the mixes above and about 1.3mg on another.

Why the calculator at the top of this page has a syringe selector: every unit count in the tables above is a U-100 count, and the second row of the scale table is the reason that has to be said out loud. The selector exists so the barrel is a stated input rather than an assumption, and the arithmetic of the two scales is worked through separately.

How many units is 2mg of GHK-Cu?

The honest answer is a range: at 25mg per mL (a 50mg vial plus 2mL of water), 2mg reads as 8 units on a U-100 syringe. At about 16.7mg per mL (the same vial plus 3mL), the same 2mg reads as 12 units.

Four water volumes, four different answers to the same question: the reconstitution table further up puts that same 2mg at 4, 8, 12 and 20 units on a 50mg vial alone, depending only on how much water went in. The question has as many answers as the vial has plausible mixes, which is why our dose math index treats the water volume as the input that decides everything downstream.

What's not known yet?

What the FDA record actually contains: injectable GHK-Cu appears there as a compounding nomination, not as an approved drug. The agency lists "GHK-Cu (for injectable routes of administration)" among bulk drug substances nominated but withdrawn, a list it describes as substances previously in category 2 of the interim policies that the nominators withdrew, on a page whose content is current as of 22 April 2026.

Why that leaves no approved route in: the 503A bulks list itself sits in the Code of Federal Regulations at 21 CFR 216.23, and it names six substances, not one of them a peptide. So injectable GHK-Cu is not a substance a 503A pharmacy can compound from under that provision, and searching the openFDA drug label API for GHK-Cu, and again for glycyl-l-histidyl-l-lysine, as a substance name returned no matches on 30 July 2026, HTTP 404 both times, so there is no labeled product on that database for a prescription to point at. What none of that establishes is where any particular vial sold online came from or what is in it. We have not surveyed vendors, we hold no provenance record for any of them, and this page makes no claim about one. Topical copper peptide spans cosmetics and wound-care trials, and it is the lane the human trials actually studied.

What the record does not contain:

• No human trial of injected GHK-Cu at any dose. The only injected doses in the cited record are in mice.
• No injectable human trial data. The 2026 sports-medicine review reports no clinical data supporting GHK-Cu for musculoskeletal use, and lists indications, dosing, frequency and duration as unknown across the peptides it reviews.
• No verified data on the community protocols that dominate online discussion. None of it has been tested in a controlled trial.
• No registry record we can rely on for GHK-Cu in any form, injected or topical. ClinicalTrials.gov, searched through its own API on 2 August 2026, returns three records for GHK-Cu and not one we can stand behind administers it: one is a device and serum facial-treatment study, one measures circulating GHK levels after a patch, and the third is a registered topical GHK-Cu gel study, removed from this page on that date for the reason given in the sourcing section.

Every injected human figure on this page therefore traces to the chart's last row, the one with no study behind it.

What we could not find a specification in: the sources cited on this page contain no compendial monograph for GHK-Cu and no FDA-reviewed specification for an injectable form, and the openFDA searches above returned nothing on 30 July 2026. We did not run a systematic compendial search and we cannot see inside any vendor's own release testing, so read that as what our searches did not surface, not as proof that no specification exists anywhere. We found no assay of a research-grade vial in the literature we pulled.

What a listing asks you to believe: identity, purity, sterility, and the concentration printed on the label.

The thing we would check before anything else: whether the vial holds what it says it holds. On a compound whose only human evidence is a cream, an injectable vial is unstudied and unverified at the same time, and those are two separate problems.

How this page is sourced

Reviews are labeled as reviews: every research figure above came from the cited paper itself, and where the source summarizes other work rather than reporting its own, this page says so in the sentence.

The nine sources, and what kind each is: six peer-reviewed papers with their DOIs and PubMed IDs, one trial registry search with its query and its date, and two regulator documents carrying every approval and compounding line above. Each is listed below with its identifier, and every figure on this page traces back to one of them.

How we decide what counts as a source: that test is written out on the methodology page, and a correction to anything above lands there before it lands here.

What we got wrong until 30 July 2026, stated plainly: three things, all of them the page claiming more than its sources carry. The chart classified the 2026 sports-medicine review under species Human and route Injection, which reads as a human injection study; it is a narrative review, and its finding on GHK-Cu is that no clinical data supports musculoskeletal use. The regulatory paragraph said the injectable vials sold online sit outside the approved-drug system entirely, which is a claim about every vendor's supply chain that no document here supports; it now says only what the regulation and the openFDA searches establish. And the vial paragraph asserted that a research-grade vial ships against no monograph and no reviewed specification anywhere, which is an absence claim over a whole compendium; it now reports what our searches did and did not surface, with the date.

What we cut on 2 August 2026, stated plainly: this page carried registry record NCT07437586 as a recruiting phase 2 of a 0.1% w/w topical GHK-Cu gel, 60 participants planned, once daily for 14 days. It was a row on the dosage chart, a frequency in the cycle-length section, a bullet in the unknowns list and a reference entry. All four are gone. The sponsor named on that record has eight studies on ClinicalTrials.gov, two of which describe themselves as specimens in their own summaries, one opening "This fictional study is an example of a ClinicalTrials.gov-style record". All eight share one facility and one pair of contact addresses, on an email domain that does not match the sponsor's name, and one carries a study identifier prefixed EX. We cannot show that NCT07437586 is a fabrication and we are not claiming it. We are saying it cannot carry the weight this page put on it, which was the only human trial figure here still in progress, and our rule is that such a claim is cut rather than softened. What replaces it is the finding we can stand behind: on a registry search we ran and printed, no registry record we can rely on administers GHK-Cu to people, by any route, in any form.

Last reviewed: 19 July 2026.

1. 1

   Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520.

2. 2

   Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61. doi:10.31491/apt.2020.03.014. PMID 35083444.

3. 3

   Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. doi:10.1001/archfaci.8.4.252. PMID 16847171.

4. 4

   Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. doi:10.1067/mva.1992.37086. PMID 1495150.

5. 5

   Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. doi:10.3389/fmolb.2022.925700. PMID 35936787.

6. 6

   Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. Study design is stated in the abstract as a narrative review; the GHK-Cu finding and the unknown indications, dosing, frequency and duration are in its Results and Conclusion. Re-read 30 July 2026 from the PubMed record, HTTP 200. doi:10.1177/03635465251357593. PMID 41476424.

7. 7

   ClinicalTrials.gov, searched for GHK-Cu through the registry API on 2 August 2026, HTTP 200. That term returns three records and the term glycyl-histidyl-lysine returns none. Two of the three administer no GHK-Cu to anyone: NCT05932732 is a completed open-label phase 4 of three device-delivered facial treatments with a serum booster, and NCT07706361 is a not-yet-recruiting study measuring circulating GHK and GHK-Cu blood levels after a topical patch. The third is the record withdrawn from this page, described in the correction above.

8. 8

   U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, including the table headed "Bulk drug substances nominated but withdrawn", which carries the entry "GHK-Cu (for injectable routes of administration)". Content current as of 22 April 2026. Retrieved 29 July 2026, HTTP 200. fda.gov, category 2 and withdrawn nominations.

9. 9

   21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. The list in paragraph (a) names Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. Source note 84 FR 4710, 19 February 2019. Retrieved from the eCFR 29 July 2026, HTTP 200. eCFR, section 216.23.